Options Brief: Cell Therapeutics (CTIC)

Shares of Cell Therapeutics CTIC are lower on the session by 1.67%, trading at $0.3835. Overall call volume is now running at 6.10x the daily average, with 74% of all calls traded being purchases on the offer. 8,893 contracts have traded on the session so far. Cell Therapeutics, Inc. develops, acquires and commercializes treatments for cancer. It focuses on building a biopharmaceutical company with a diversified portfolio of oncology drugs. Its research, development, acquisition and in-licensing activities concentrate on identifying and developing less toxic ways to treat cancer.